Spectrum Pharmaceutecals Inc (SPPI)

[Ville7]

" The US mBC trial is for HER2 patients, w the protocol last updated in Oct 2016. So what are the odds that they'll will modify the protocol to include EGFR mutations? Just something to ponder. "

The decision to include HER exon 20 was made by MD Anderson, not SPPI. I trust them. But i don't trust SPPI. And as a shareholder since 2005 one should have learned his lesson. But if someone independent says the drug has high promises then my ears are open. And i trust even Hamni more than Raj an Joe. Still miserable and greedy management, that hasn't changed.... but they probably sit on two good drugs. And at least one that could sell from alone (poziotinib)...

If they make decisions to include a wider set of patients it could be because of other reasons - f.e. to speed up the enrollement. Like they decided to cut the rolontis trial to 400 to keep the promise to deliver data in the first half of 2018 and because they where hinted by the FDA that they have to do a second trial - which they take a high risk with only shortly above 200 patients. They increase the risk in rolontis significantly and they abandon the chance to show superiority...